See­los Ther­a­peu­tics 'tem­porar­i­ly' stops study in rare neu­ro dis­or­der for busi­ness rea­sons

Mi­cro­cap biotech See­los Ther­a­peu­tics is halt­ing en­roll­ment of its study in spin­ocere­bel­lar atax­ia type 3 (al­so known as Macha­do-Joseph dis­ease) be­cause of “fi­nan­cial con­sid­er­a­tions,” and in or­der to fo­cus on oth­er stud­ies, the com­pa­ny said to­day, adding that the pause would be tem­po­rary.

The study will con­tin­ue with the pa­tients who have al­ready en­rolled, and the da­ta from them will be used to de­cide whether to con­tin­ue en­rolling oth­ers in the fu­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER